{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:49:46Z","timestamp":1794534586033,"version":"4.9.1"},"reference-count":279,"publisher":"European Respiratory Society (ERS)","issue":"179","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a severe disease characterised by a progressive thickening and obliteration of pulmonary vessels, resulting in increased vascular resistance, elevated pulmonary artery pressures, and right heart failure. Among the various conditions associated with PAH, systemic sclerosis (SSc) is the most common in Western countries. Compared to other forms of PAH, SSc-PAH presents with a more aggressive clinical course, poorer response to conventional therapies and a worse prognosis. However, despite these differences, the overall management of SSc-PAH remains close to idiopathic PAH; and therefore, there is a crucial need for treatment strategies dedicated to this disease. To help fill this gap, we assessed the level of evidence currently available on SSc-PAH management in a systematic literature review that compiled data regarding conventional therapies, immunosuppressants, nonconventional drugs and surgical\/interventional procedures. For each study, we highlighted the results specific to the connective tissue disease or SSc subgroups, the haemodynamic characteristics of the patients, and their comorbidities. By doing so, we identified critical gaps in the field, consisting mostly of the lack of studies focusing on SSc-PAH, a substantial heterogeneity in haemodynamic severity (with notable scarcity of data for mild PAH) and the systematic exclusion of relevant comorbidities (such as interstitial lung disease). Building on these data and our cumulative experience, we provide pragmatic, experience-based suggestions tailored to the management of SSc-PAH, that tries to capture the full scope of clinical situations encountered in these patients and help clinicians manage difficult cases where robust data are lacking.<\/jats:p>","DOI":"10.1183\/16000617.0137-2025","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:26:39Z","timestamp":1790789199000},"page":"250137","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons"],"prefix":"10.1183","volume":"35","author":[{"given":"Annalisa","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Sanges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-8093","authenticated-orcid":false,"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Godinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-9809","authenticated-orcid":false,"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-1817","authenticated-orcid":false,"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026093007330991000_35.179.250137.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2026093007330991000_35.179.250137.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02419-2021"},{"key":"2026093007330991000_35.179.250137.3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-015-0560-x","article-title":"Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH)","volume":"18","author":"Sobanski","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2026093007330991000_35.179.250137.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22069"},{"key":"2026093007330991000_35.179.250137.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1456OC"},{"key":"2026093007330991000_35.179.250137.6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MCP.0000000000001001","article-title":"Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?","volume":"29","author":"Khan","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026093007330991000_35.179.250137.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103514"},{"key":"2026093007330991000_35.179.250137.8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.revmed.2023.10.450","article-title":"Pulmonary hypertension in connective tissue diseases: what every CTD specialist should know \u2013 but is afraid to ask!","volume":"45","author":"Sanges","year":"2024","journal-title":"Rev M\u00e9d Interne"},{"key":"2026093007330991000_35.179.250137.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"2026093007330991000_35.179.250137.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2026093007330991000_35.179.250137.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.21433"},{"key":"2026093007330991000_35.179.250137.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203301"},{"key":"2026093007330991000_35.179.250137.13","doi-asserted-by":"publisher","DOI":"10.1186\/ar3876"},{"key":"2026093007330991000_35.179.250137.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02205-4"},{"key":"2026093007330991000_35.179.250137.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01197-2017"},{"key":"2026093007330991000_35.179.250137.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"2026093007330991000_35.179.250137.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nepr.2021.103194"},{"key":"2026093007330991000_35.179.250137.18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4103\/0019-5413.139827","article-title":"Medical subject headings (MeSH) terms","volume":"48","author":"Dhammi","year":"2014","journal-title":"Indian J Orthop"},{"key":"2026093007330991000_35.179.250137.19","unstructured":"Howick J , Chalmers I , Glasziou P , et al. The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine. 2011. www.cebm.net\/wp-content\/uploads\/2014\/06\/CEBM-Levels-of-Evidence-Introduction-2.1.pdf"},{"key":"2026093007330991000_35.179.250137.20","unstructured":"Wells GA , Wells G , Shea B , et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2026093007330991000_35.179.250137.21","unstructured":"Higgins JPT , Thomas J , Chandler J , et al. eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane. 2023. www.training.cochrane.org\/handbook"},{"key":"2026093007330991000_35.179.250137.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2466-5"},{"key":"2026093007330991000_35.179.250137.23","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"key":"2026093007330991000_35.179.250137.24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2017.02.094","article-title":"Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease","volume":"235","author":"Gali\u00e8","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026093007330991000_35.179.250137.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0263"},{"key":"2026093007330991000_35.179.250137.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.05.004"},{"key":"2026093007330991000_35.179.250137.27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026093007330991000_35.179.250137.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209087"},{"key":"2026093007330991000_35.179.250137.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep398"},{"key":"2026093007330991000_35.179.250137.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048967"},{"key":"2026093007330991000_35.179.250137.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2026093007330991000_35.179.250137.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.179"},{"key":"2026093007330991000_35.179.250137.33","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases","volume":"67","author":"Denton","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026093007330991000_35.179.250137.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.11.009"},{"key":"2026093007330991000_35.179.250137.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01688.x"},{"key":"2026093007330991000_35.179.250137.36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026093007330991000_35.179.250137.37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","article-title":"Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) \u2013 a subgroup analysis of the ARIES-E clinical trial","volume":"117","author":"Fischer","year":"2016","journal-title":"Respir Med"},{"key":"2026093007330991000_35.179.250137.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00279.x"},{"key":"2026093007330991000_35.179.250137.39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12872-020-01591-1","article-title":"Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post hoc analysis","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2026093007330991000_35.179.250137.40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03363-0"},{"key":"2026093007330991000_35.179.250137.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2014.07.013"},{"key":"2026093007330991000_35.179.250137.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081277"},{"key":"2026093007330991000_35.179.250137.43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2026093007330991000_35.179.250137.44","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.50.513"},{"key":"2026093007330991000_35.179.250137.45","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.2.420"},{"key":"2026093007330991000_35.179.250137.46","first-page":"2252","article-title":"Aerosolized iloprost in CREST syndrome related pulmonary hypertension","volume":"28","author":"Launay","year":"2001","journal-title":"J Rheumatol"},{"key":"2026093007330991000_35.179.250137.47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann Intern Med"},{"key":"2026093007330991000_35.179.250137.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"2026093007330991000_35.179.250137.49","first-page":"88","article-title":"Iloprost as adjuvant to sildenafil in connective tissue disease-associated pulmonary hypertension","volume":"14","author":"Otair","year":"2013","journal-title":"Turk Thorac J"},{"key":"2026093007330991000_35.179.250137.50","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/art.1780371018","article-title":"Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases","volume":"37","author":"de la Mata","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026093007330991000_35.179.250137.51","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02493-2016"},{"key":"2026093007330991000_35.179.250137.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02044-2014"},{"key":"2026093007330991000_35.179.250137.53","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00081706"},{"key":"2026093007330991000_35.179.250137.54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12872-017-0674-3","article-title":"Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026093007330991000_35.179.250137.55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216274"},{"key":"2026093007330991000_35.179.250137.56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.201704-0789LE","article-title":"Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma-associated pulmonary arterial hypertension","volume":"197","author":"Mercurio","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093007330991000_35.179.250137.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210236"},{"key":"2026093007330991000_35.179.250137.58","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1398OC"},{"key":"2026093007330991000_35.179.250137.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.02.019"},{"key":"2026093007330991000_35.179.250137.60","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"2026093007330991000_35.179.250137.61","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.1.182"},{"key":"2026093007330991000_35.179.250137.62","doi-asserted-by":"publisher","DOI":"10.1002\/art.23303"},{"key":"2026093007330991000_35.179.250137.63","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-0473"},{"key":"2026093007330991000_35.179.250137.64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","article-title":"Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease","volume":"82","author":"Yasuoka","year":"2018","journal-title":"Circ J"},{"key":"2026093007330991000_35.179.250137.65","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu509oa"},{"key":"2026093007330991000_35.179.250137.66","first-page":"282","article-title":"Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment","volume":"29","author":"Tanaka","year":"2002","journal-title":"J Rheumatol"},{"key":"2026093007330991000_35.179.250137.67","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3481OC"},{"key":"2026093007330991000_35.179.250137.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02463-2020"},{"key":"2026093007330991000_35.179.250137.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-2061LE"},{"key":"2026093007330991000_35.179.250137.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02449-2016"},{"key":"2026093007330991000_35.179.250137.71","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952"},{"key":"2026093007330991000_35.179.250137.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"2026093007330991000_35.179.250137.73","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"2026093007330991000_35.179.250137.74","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.217"},{"key":"2026093007330991000_35.179.250137.75","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2026093007330991000_35.179.250137.76","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2026093007330991000_35.179.250137.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.05.025"},{"key":"2026093007330991000_35.179.250137.78","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000381923","article-title":"Efficacy and safety of long-term imatinib therapy for pulmonary arterial hypertension","volume":"89","author":"Speich","year":"2015","journal-title":"Respiration"},{"key":"2026093007330991000_35.179.250137.79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Frantz","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026093007330991000_35.179.250137.80","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1660::AID-ART289>3.0.CO;2-W"},{"key":"2026093007330991000_35.179.250137.81","first-page":"1066","article-title":"Balloon dilation atrial septostomy for advanced pulmonary hypertension in patients on prostanoid therapy","volume":"85","author":"Kuhn","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026093007330991000_35.179.250137.82","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00072210"},{"key":"2026093007330991000_35.179.250137.83","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.9.797"},{"key":"2026093007330991000_35.179.250137.84","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00416-6"},{"key":"2026093007330991000_35.179.250137.85","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.recesp.2015.09.011","article-title":"Use of atrial septostomy to treat severe pulmonary arterial hypertension in adults","volume":"69","author":"Vel\u00e1zquez Mart\u00edn","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"2026093007330991000_35.179.250137.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2006.02.002"},{"key":"2026093007330991000_35.179.250137.87","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1344"},{"key":"2026093007330991000_35.179.250137.88","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jcin.2022.09.013","article-title":"Pulmonary artery denervation for pulmonary arterial hypertension: a sham-controlled randomized PADN-CFDA trial","volume":"15","author":"Zhang","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026093007330991000_35.179.250137.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.12.027"},{"key":"2026093007330991000_35.179.250137.90","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837"},{"key":"2026093007330991000_35.179.250137.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2014.01.020"},{"key":"2026093007330991000_35.179.250137.92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.00958.x"},{"key":"2026093007330991000_35.179.250137.93","first-page":"1018","article-title":"Indications and outcomes in adult lung transplantation","volume":"6","author":"Whitson","year":"2014","journal-title":"J Thorac Dis"},{"key":"2026093007330991000_35.179.250137.94","doi-asserted-by":"publisher","DOI":"10.1002\/art.22264"},{"key":"2026093007330991000_35.179.250137.95","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0017-x"},{"key":"2026093007330991000_35.179.250137.96","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Prad\u00e8re","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026093007330991000_35.179.250137.97","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139809"},{"key":"2026093007330991000_35.179.250137.98","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026093007330991000_35.179.250137.99","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182845f23"},{"key":"2026093007330991000_35.179.250137.100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026093007330991000_35.179.250137.101","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.athoracsur.2017.09.038","article-title":"Long-term survival in bilateral lung transplantation for scleroderma-related lung disease","volume":"105","author":"Chan","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2026093007330991000_35.179.250137.102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2017.03.012","article-title":"Lung transplantation in systemic sclerosis: a single center cohort study","volume":"85","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2026093007330991000_35.179.250137.103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2026093007330991000_35.179.250137.104","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0969"},{"key":"2026093007330991000_35.179.250137.105","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1411OC"},{"key":"2026093007330991000_35.179.250137.106","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2026093007330991000_35.179.250137.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.11.009"},{"key":"2026093007330991000_35.179.250137.108","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0093OC"},{"key":"2026093007330991000_35.179.250137.109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12931-022-02262-9","article-title":"Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design","volume":"23","author":"Benza","year":"2022","journal-title":"Respir Res"},{"key":"2026093007330991000_35.179.250137.110","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.clinthera.2019.05.006","article-title":"Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIb clinical trial","volume":"41","author":"Chang","year":"2019","journal-title":"Clin Ther"},{"key":"2026093007330991000_35.179.250137.111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"2026093007330991000_35.179.250137.112","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090614"},{"key":"2026093007330991000_35.179.250137.113","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00105914"},{"key":"2026093007330991000_35.179.250137.114","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01110-2024"},{"key":"2026093007330991000_35.179.250137.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107065"},{"key":"2026093007330991000_35.179.250137.116","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"2026093007330991000_35.179.250137.117","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(02)80029-7"},{"key":"2026093007330991000_35.179.250137.118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2026093007330991000_35.179.250137.119","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00380-014-0544-1","article-title":"Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension","volume":"30","author":"Hatano","year":"2015","journal-title":"Heart Vessels"},{"key":"2026093007330991000_35.179.250137.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.09.020"},{"key":"2026093007330991000_35.179.250137.121","doi-asserted-by":"publisher","DOI":"10.1002\/art.22634"},{"key":"2026093007330991000_35.179.250137.122","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1185\/030079906X167390","article-title":"Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients","volume":"23","author":"Sasayama","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2026093007330991000_35.179.250137.123","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.5.1471"},{"key":"2026093007330991000_35.179.250137.124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1253\/circj.69.131","article-title":"Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension","volume":"69","author":"Sasayama","year":"2005","journal-title":"Circ J"},{"key":"2026093007330991000_35.179.250137.125","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00121-9"},{"key":"2026093007330991000_35.179.250137.126","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.069484"},{"key":"2026093007330991000_35.179.250137.127","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2026093007330991000_35.179.250137.128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12872-016-0361-9","article-title":"Evaluation of efficacy, safety and tolerability of ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study","volume":"16","author":"Huo","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026093007330991000_35.179.250137.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.06.040"},{"key":"2026093007330991000_35.179.250137.130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1185\/03007995.2012.685930","article-title":"Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension","volume":"28","author":"Yoshida","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2026093007330991000_35.179.250137.131","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.605440"},{"key":"2026093007330991000_35.179.250137.132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"2026093007330991000_35.179.250137.133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"2026093007330991000_35.179.250137.134","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1028"},{"key":"2026093007330991000_35.179.250137.135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1253\/circj.CJ-15-1305","article-title":"Efficacy and safety of a novel endothelin receptor antagonist, macitentan, in Japanese patients with pulmonary arterial hypertension","volume":"80","author":"Tahara","year":"2016","journal-title":"Circ J"},{"key":"2026093007330991000_35.179.250137.136","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/03007995.2020.1756234","article-title":"Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients","volume":"36","author":"Tahara","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2026093007330991000_35.179.250137.137","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.chest.2016.08.1473","article-title":"Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trail","volume":"151","author":"Mehta","year":"2017","journal-title":"Chest"},{"key":"2026093007330991000_35.179.250137.138","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/lungindia.lungindia_671_20","article-title":"The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up","volume":"39","author":"Jariwala","year":"2022","journal-title":"Lung India"},{"key":"2026093007330991000_35.179.250137.139","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","article-title":"Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension","volume":"39","author":"Souza","year":"2022","journal-title":"Adv Ther"},{"key":"2026093007330991000_35.179.250137.140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2026093007330991000_35.179.250137.141","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00364-2015"},{"key":"2026093007330991000_35.179.250137.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2021.07.027"},{"key":"2026093007330991000_35.179.250137.143","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2026093007330991000_35.179.250137.144","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12931-022-02296-z","article-title":"Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri\u00ae): a prospective, 6-months, open label, observational, non-interventional study","volume":"24","author":"Degering","year":"2023","journal-title":"Respir Res"},{"key":"2026093007330991000_35.179.250137.145","doi-asserted-by":"publisher","DOI":"10.1253\/circj.71.1829"},{"key":"2026093007330991000_35.179.250137.146","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"2026093007330991000_35.179.250137.147","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"2026093007330991000_35.179.250137.148","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.5.1561"},{"key":"2026093007330991000_35.179.250137.149","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2026093007330991000_35.179.250137.150","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.06.008"},{"key":"2026093007330991000_35.179.250137.151","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.healun.2018.06.006","article-title":"Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension","volume":"37","author":"Richter","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026093007330991000_35.179.250137.152","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.09.005"},{"key":"2026093007330991000_35.179.250137.153","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000531169","article-title":"Long-term safety, outcome, and clinical effects of subcutaneous and intravenous treprostinil treatment in patients with severe chronic pulmonary arterial hypertension","volume":"102","author":"Harutyunova","year":"2023","journal-title":"Respiration"},{"key":"2026093007330991000_35.179.250137.154","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2118"},{"key":"2026093007330991000_35.179.250137.155","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00044406"},{"key":"2026093007330991000_35.179.250137.156","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.08.019"},{"key":"2026093007330991000_35.179.250137.157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2026093007330991000_35.179.250137.158","doi-asserted-by":"crossref","first-page":"e12119","DOI":"10.1002\/pul2.12119","article-title":"INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)","volume":"12","author":"Hill","year":"2022","journal-title":"Pulm Circ"},{"key":"2026093007330991000_35.179.250137.159","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.124388"},{"key":"2026093007330991000_35.179.250137.160","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"2026093007330991000_35.179.250137.161","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2875"},{"key":"2026093007330991000_35.179.250137.162","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1640OC"},{"key":"2026093007330991000_35.179.250137.163","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"2026093007330991000_35.179.250137.164","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.21987","article-title":"Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study","volume":"35","author":"Sun","year":"2012","journal-title":"Clin Cardiol"},{"key":"2026093007330991000_35.179.250137.165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1183\/09031936.01.17100080","article-title":"Long-term treatment of pulmonary hypertension with aerosolized iloprost","volume":"17","author":"Machherndl","year":"2001","journal-title":"Eur Respir J"},{"key":"2026093007330991000_35.179.250137.166","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.01.008"},{"key":"2026093007330991000_35.179.250137.167","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00130408"},{"key":"2026093007330991000_35.179.250137.168","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.healun.2018.09.003","article-title":"Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study","volume":"38","author":"Frost","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2026093007330991000_35.179.250137.169","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.chest.2021.01.066","article-title":"Relationship between time from diagnosis and morbidity\/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study","volume":"160","author":"Gaine","year":"2021","journal-title":"Chest"},{"key":"2026093007330991000_35.179.250137.170","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01898-1"},{"key":"2026093007330991000_35.179.250137.171","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.chest.2022.08.2231","article-title":"Assessing daily life physical activity by actigraphy in pulmonary arterial hypertension: insights from the randomized controlled study with selexipag (TRACE)","volume":"163","author":"Howard","year":"2023","journal-title":"Chest"},{"key":"2026093007330991000_35.179.250137.172","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12931-020-01594-8","article-title":"Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study","volume":"22","author":"Klose","year":"2021","journal-title":"Respir Res"},{"key":"2026093007330991000_35.179.250137.173","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.healun.2017.09.024","article-title":"Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study","volume":"37","author":"Preston","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026093007330991000_35.179.250137.174","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2369"},{"key":"2026093007330991000_35.179.250137.175","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1253\/circj.CJ-16-1348","article-title":"Efficacy and safety of an orally administered selective prostacyclin receptor agonist, selexipag, in Japanese patients with pulmonary arterial hypertension","volume":"81","author":"Tanabe","year":"2017","journal-title":"Circ J"},{"key":"2026093007330991000_35.179.250137.176","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2026093007330991000_35.179.250137.177","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"2026093007330991000_35.179.250137.178","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01030-2019"},{"key":"2026093007330991000_35.179.250137.179","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12325-023-02769-7","article-title":"Ralinepag phase II open-label extension study in patients with pulmonary arterial hypertension","volume":"41","author":"Barber\u00e0","year":"2024","journal-title":"Adv Ther"},{"key":"2026093007330991000_35.179.250137.180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000470916","article-title":"Plasma drug concentrations in patients with pulmonary arterial hypertension on combination treatment","volume":"94","author":"Gr\u00fcnig","year":"2017","journal-title":"Respiration"},{"key":"2026093007330991000_35.179.250137.181","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.rmed.2017.03.025","article-title":"Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)","volume":"126","author":"Shapiro","year":"2017","journal-title":"Respir Med"},{"key":"2026093007330991000_35.179.250137.182","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertens Res"},{"key":"2026093007330991000_35.179.250137.183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2026093007330991000_35.179.250137.184","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12931-019-1180-1","article-title":"Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension","volume":"20","author":"White","year":"2019","journal-title":"Respir Res"},{"key":"2026093007330991000_35.179.250137.185","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-2600(16)30307-1","article-title":"Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026093007330991000_35.179.250137.186","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093007330991000_35.179.250137.187","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026093007330991000_35.179.250137.188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","article-title":"Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN Trial","volume":"18","author":"Jansa","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026093007330991000_35.179.250137.189","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00673-2020"},{"key":"2026093007330991000_35.179.250137.190","doi-asserted-by":"crossref","unstructured":"Sulica R , Sangli S , Chakravarti A , et al. Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. Pulm Circ 2019; 9: 2045894019826944. doi:10.1177\/2045894019826944","DOI":"10.1177\/2045894019826944"},{"key":"2026093007330991000_35.179.250137.191","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2026093007330991000_35.179.250137.192","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026093007330991000_35.179.250137.193","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026093007330991000_35.179.250137.194","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026093007330991000_35.179.250137.195","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"2026093007330991000_35.179.250137.196","doi-asserted-by":"crossref","first-page":"954007","DOI":"10.3389\/fimmu.2022.954007","article-title":"Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension","volume":"13","author":"Sanges","year":"2022","journal-title":"Front Immunol"},{"key":"2026093007330991000_35.179.250137.197","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01949-2023"},{"key":"2026093007330991000_35.179.250137.198","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2014.09.101","article-title":"Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study","volume":"177","author":"Jiang","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026093007330991000_35.179.250137.199","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1699OC"},{"key":"2026093007330991000_35.179.250137.200","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"2026093007330991000_35.179.250137.201","doi-asserted-by":"crossref","first-page":"e12352","DOI":"10.1002\/pul2.12352","article-title":"IMPAHCT: a randomized phase 2b\/3 study of inhaled imatinib for pulmonary arterial hypertension","volume":"14","author":"Gillies","year":"2024","journal-title":"Pulm Circ"},{"key":"2026093007330991000_35.179.250137.202","unstructured":"Tenax Therapeutics. Tenax Therapeutics announces successful comparative pharmacokinetic study of TNX-201 for the treatment of pulmonary arterial hypertension. Date last updated: 23 May 2022. Date last accessed: 18 November 2025. https:\/\/investors.tenaxthera.com\/news-releases\/news-release-details\/tenax-therapeutics-announces-successful-comparative"},{"key":"2026093007330991000_35.179.250137.203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-2600(21)00032-1","article-title":"Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"10","author":"Rosenkranz","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026093007330991000_35.179.250137.204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.201605-1024OC","article-title":"Anastrozole in pulmonary arterial hypertension. A randomized, double-blind, placebo-controlled trial","volume":"195","author":"Kawut","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093007330991000_35.179.250137.205","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1164\/rccm.202402-0371OC","article-title":"Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial","volume":"210","author":"Kawut","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093007330991000_35.179.250137.206","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacbts.2018.01.013","article-title":"Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension","volume":"3","author":"Brash","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026093007330991000_35.179.250137.207","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149011"},{"key":"2026093007330991000_35.179.250137.208","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.015693"},{"key":"2026093007330991000_35.179.250137.209","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.4.1446"},{"key":"2026093007330991000_35.179.250137.210","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001429"},{"key":"2026093007330991000_35.179.250137.211","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.01.368"},{"key":"2026093007330991000_35.179.250137.212","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00215514"},{"key":"2026093007330991000_35.179.250137.213","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-2025LE"},{"key":"2026093007330991000_35.179.250137.214","doi-asserted-by":"crossref","first-page":"e021518","DOI":"10.1161\/JAHA.121.021518","article-title":"Carvedilol for treatment of right ventricular dysfunction in pulmonary arterial hypertension","volume":"10","author":"Thenappan","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026093007330991000_35.179.250137.215","doi-asserted-by":"crossref","first-page":"e95240","DOI":"10.1172\/jci.insight.95240","article-title":"Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial","volume":"2","author":"Farha","year":"2017","journal-title":"JCI Insight"},{"key":"2026093007330991000_35.179.250137.216","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/23971983211016196","article-title":"A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis","volume":"6","author":"Kong","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2026093007330991000_35.179.250137.217","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0443"},{"key":"2026093007330991000_35.179.250137.218","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2015.33"},{"key":"2026093007330991000_35.179.250137.219","doi-asserted-by":"publisher","DOI":"10.1253\/circj.70.174"},{"key":"2026093007330991000_35.179.250137.220","doi-asserted-by":"crossref","unstructured":"Sodimu A , Bartolome S , Igenoza OP , et al. Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study. Pulm Circ 2020; 10: 2045894020971954. doi:10.1177\/2045894020971954","DOI":"10.1177\/2045894020971954"},{"key":"2026093007330991000_35.179.250137.221","first-page":"519","article-title":"Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis","volume":"14","author":"Seibold","year":"1987","journal-title":"J Rheumatol"},{"key":"2026093007330991000_35.179.250137.222","doi-asserted-by":"publisher","DOI":"10.1086\/682427"},{"key":"2026093007330991000_35.179.250137.223","doi-asserted-by":"crossref","first-page":"1118796","DOI":"10.3389\/fcvm.2023.1118796","article-title":"Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study","volume":"10","author":"Han","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026093007330991000_35.179.250137.224","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.10.006"},{"key":"2026093007330991000_35.179.250137.225","doi-asserted-by":"crossref","first-page":"e12024","DOI":"10.1002\/pul2.12024","article-title":"An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension","volume":"12","author":"Simon","year":"2022","journal-title":"Pulm Circ"},{"key":"2026093007330991000_35.179.250137.226","doi-asserted-by":"crossref","unstructured":"Safdar Z , Cho E . Effect of spironolactone use in pulmonary arterial hypertension \u2013 analysis from pivotal trial databases. Pulm Circ 2021; 11: 20458940211045618. doi:10.1177\/20458940211045618","DOI":"10.1177\/20458940211045618"},{"key":"2026093007330991000_35.179.250137.227","doi-asserted-by":"crossref","unstructured":"Safdar Z , Frost A , Basant A , et al. Spironolactone in pulmonary arterial hypertension: results of a cross-over study. Pulm Circ 2020; 10: 2045894019898030. doi:10.1177\/2045894019898030","DOI":"10.1177\/2045894019898030"},{"key":"2026093007330991000_35.179.250137.228","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.04.051"},{"key":"2026093007330991000_35.179.250137.229","doi-asserted-by":"crossref","unstructured":"Corkish ME , Devine LT , Clarke MM , et al. Rates of hospitalization associated with the use of aldosterone receptor antagonists in patients with pulmonary arterial hypertension. Pulm Circ 2019; 9: 2045894019868422. doi:10.1177\/2045894019868422","DOI":"10.1177\/2045894019868422"},{"key":"2026093007330991000_35.179.250137.230","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/jcm12041571","article-title":"Effects of trimetazidine on right ventricular function and ventricular remodeling in patients with pulmonary artery hypertension: a randomised controlled trial","volume":"12","author":"Verdejo","year":"2023","journal-title":"J Clin Med"},{"key":"2026093007330991000_35.179.250137.231","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01424-2024"},{"key":"2026093007330991000_35.179.250137.232","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415160"},{"key":"2026093007330991000_35.179.250137.233","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamadermatol.2018.0916","article-title":"Whole-body distribution and clinical association of telangiectases in systemic sclerosis","volume":"154","author":"Jouvray","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2026093007330991000_35.179.250137.234","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/23971983241238921","article-title":"Prevalence, causes, and clinical associations of anemia in patients with systemic sclerosis: a cohort study","volume":"9","author":"Gachet","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"2026093007330991000_35.179.250137.235","first-page":"269","article-title":"Pulmonary hypertension and right ventricular failure lung transplant versus heart\u2013lung transplant","volume":"38","author":"Huston","year":"2020","journal-title":"Cardiol Clin"},{"key":"2026093007330991000_35.179.250137.236","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivt111"},{"key":"2026093007330991000_35.179.250137.237","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1253\/circj.CJ-16-0838","article-title":"Reverse right ventricular remodeling after lung transplantation in patients with pulmonary arterial hypertension under combination therapy of targeted medical drugs","volume":"81","author":"Sarashina","year":"2017","journal-title":"Circ J"},{"key":"2026093007330991000_35.179.250137.238","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018435"},{"key":"2026093007330991000_35.179.250137.239","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004526"},{"key":"2026093007330991000_35.179.250137.240","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"2026093007330991000_35.179.250137.241","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq170"},{"key":"2026093007330991000_35.179.250137.242","doi-asserted-by":"publisher","DOI":"10.1186\/ar3883"},{"key":"2026093007330991000_35.179.250137.243","doi-asserted-by":"crossref","first-page":"22038","DOI":"10.1038\/s41598-024-70650-w","article-title":"Long-term oxygen therapy in precapillary pulmonary hypertension \u2013 SOPHA study","volume":"14","author":"Benjamin","year":"2024","journal-title":"Sci Rep"},{"key":"2026093007330991000_35.179.250137.244","doi-asserted-by":"crossref","first-page":"1900276","DOI":"10.1183\/13993003.002762019","article-title":"Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial","volume":"54","author":"Ulrich","year":"2019","journal-title":"Eur Respir J"},{"key":"2026093007330991000_35.179.250137.245","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-02892-3"},{"key":"2026093007330991000_35.179.250137.246","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-009-1176-8"},{"key":"2026093007330991000_35.179.250137.247","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1513\/AnnalsATS.201904-328RL","article-title":"Fulvestrant for the treatment of pulmonary arterial hypertension","volume":"16","author":"Kawut","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026093007330991000_35.179.250137.248","doi-asserted-by":"crossref","first-page":"e89620","DOI":"10.1172\/jci.insight.89620","article-title":"Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"1","author":"Simon","year":"2016","journal-title":"JCI Insight"},{"key":"2026093007330991000_35.179.250137.249","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1086\/683813","article-title":"Phase I safety study of ranolazine in pulmonary arterial hypertension","volume":"5","author":"Gomberg-Maitland","year":"2015","journal-title":"Pulm Circ"},{"key":"2026093007330991000_35.179.250137.250","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000581"},{"key":"2026093007330991000_35.179.250137.251","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/art.39220","article-title":"Adverse events in connective tissue disease\u2013associated pulmonary arterial hypertension","volume":"67","author":"Rhee","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026093007330991000_35.179.250137.252","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.41669","article-title":"Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026093007330991000_35.179.250137.253","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.9906015"},{"key":"2026093007330991000_35.179.250137.254","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207336"},{"key":"2026093007330991000_35.179.250137.255","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00038903"},{"key":"2026093007330991000_35.179.250137.256","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/1756-185X.14368","article-title":"Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: a systematic review","volume":"25","author":"Ding","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2026093007330991000_35.179.250137.257","doi-asserted-by":"crossref","first-page":"904631","DOI":"10.3389\/fimmu.2022.904631","article-title":"Effects of immunoglobulins G from systemic sclerosis patients in normal dermal fibroblasts: a multi-omics study","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"2026093007330991000_35.179.250137.258","doi-asserted-by":"publisher","DOI":"10.1002\/art.37838"},{"key":"2026093007330991000_35.179.250137.259","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200546"},{"key":"2026093007330991000_35.179.250137.260","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0056-2017"},{"key":"2026093007330991000_35.179.250137.261","doi-asserted-by":"publisher","DOI":"10.1002\/art.34501"},{"key":"2026093007330991000_35.179.250137.262","doi-asserted-by":"crossref","unstructured":"Morrisroe K , Hansen D , Stevens W , et al. Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis. Rheumatology 2024; keae166. doi:10.1093\/rheumatology\/keae166","DOI":"10.1093\/rheumatology\/keae166"},{"key":"2026093007330991000_35.179.250137.263","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00091212"},{"key":"2026093007330991000_35.179.250137.264","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01483-2021"},{"key":"2026093007330991000_35.179.250137.265","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02427-2017"},{"key":"2026093007330991000_35.179.250137.266","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.202401-0089PP","article-title":"Constructing the framework for disease modification in pulmonary arterial hypertension","volume":"209","author":"Zamanian","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093007330991000_35.179.250137.267","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223237"},{"key":"2026093007330991000_35.179.250137.268","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0173-2024"},{"key":"2026093007330991000_35.179.250137.269","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325-2024"},{"key":"2026093007330991000_35.179.250137.270","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01200-2024"},{"key":"2026093007330991000_35.179.250137.271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2026093007330991000_35.179.250137.272","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026093007330991000_35.179.250137.273","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2026093007330991000_35.179.250137.274","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.983866"},{"key":"2026093007330991000_35.179.250137.275","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002110"},{"key":"2026093007330991000_35.179.250137.276","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130658"},{"key":"2026093007330991000_35.179.250137.277","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207001"},{"key":"2026093007330991000_35.179.250137.278","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/00015385.2024.2408130","article-title":"A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension","volume":"79","author":"Vachi\u00e9ry","year":"2024","journal-title":"Acta Cardiol"},{"key":"2026093007330991000_35.179.250137.279","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0137-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:26:53Z","timestamp":1790789213000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0137-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":279,"journal-issue":{"issue":"179","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/16000617.0137-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0137-2025","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/16000617.0137-2025.supp1","asserted-by":"subject"}]},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}